Wedbush Reaffirms Outperform Rating for Tango Therapeutics (TNGX) [Yahoo! Finance]
Tango Therapeutics, Inc. (TNGX)
Company Research
Source: Yahoo! Finance
Tango Therapeutics Inc. (NASDAQ: TNGX ) is one of the 10 most shorted biotech stocks to buy according to hedge funds On March 6, Wedbush increased the firm's price target on Tango Therapeutics Inc. (NASDAQ:TNGX) from $15 to $19 following the company's fourth quarter financial results and corporate updates. The firm maintained an Outperform rating on the shares, with a price target indicating an upside of more than 12%. Wedbush noted that vopimetostat, a protein arginine methyltransferase 5 inhibitor, remains on track to enter its first pivotal study in 2026. The planned trial will evaluate the therapy in second-line pancreatic ductal adenocarcinoma. Wedbush Reaffirms Outperform Rating for Tango Therapeutics (TNGX) On February 23, Mizuho initiated coverage of Tango Therapeutics Inc. (NASDAQ:TNGX) with an Outperform rating and $19 price target. The firm believes that the company's lead precision oncology candidate, vopimetostat, has the potential for “first-in-class and best-in
Show less
Read more
Impact Snapshot
Event Time:
TNGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TNGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TNGX alerts
High impacting Tango Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TNGX
News
- Tango Therapeutics (TNGX) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TNGX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "holMarketBeat
- Tango Therapeutics' (TNGX) Sees Cautious Analyst Optimism Following Earnings [Yahoo! Finance]Yahoo! Finance
- Tango Therapeutics (TNGX) had its price target raised by Mizuho from $19.00 to $20.00. They now have an "outperform" rating on the stock.MarketBeat
- Tango Therapeutics (TNGX) had its price target raised by Stifel Nicolaus from $15.00 to $24.00. They now have a "buy" rating on the stock.MarketBeat
- Tango Therapeutics (TNGX) Soars 52% on Buy Reco [Yahoo! Finance]Yahoo! Finance
TNGX
Earnings
- 3/5/26 - Beat
TNGX
Sec Filings
- 3/9/26 - Form 4
- 3/5/26 - Form 144
- 3/5/26 - Form S-8
- TNGX's page on the SEC website